Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,515 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07612176RecruitingPhase 1
Testing NEOK001 drug for advanced solid tumors
This study tests a new cancer drug called NEOK001 that targets two proteins (B7-H3 and ROR1) found on certain tumor cells. The drug combines a cancer-fighting molecule with a toxic payload to kill cancer cells while sparing healthy tissue.
New York, New YorkAges 18 years+ - NCT07606612RecruitingPhase 1
Testing SI-B036 in Advanced Solid Tumors
This early-stage trial tests a new drug called SI-B036 in patients with advanced cancers that have spread or cannot be completely removed by surgery. The goal is to understand how safe the drug is and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT06714604RecruitingPhase 3
Comparing standard vs. longer chemo before pancreatic cancer surgery
This trial tests whether taking chemotherapy for a longer period before surgery can help people with borderline or locally advanced pancreatic cancer. It aims to see if a longer treatment course leads to better outcomes.
Gothenburg, VGRAges 18–90 - NCT06718205RecruitingPhase 2
Nimotuzumab plus immunotherapy and chemo for esophageal cancer
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
Zhengzhou, HenanAges 18–75 - NCT07591155RecruitingPhase 1
Testing BL-ARC002 for advanced solid tumors
This early-stage trial tests a new cancer drug called BL-ARC002 in patients whose advanced or spread cancers (solid tumors) have not responded to standard treatments. The drug is an antibody designed to help the immune system fight cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07567716Enrolling by invitation
Study of How Advanced Esophageal Cancer Spreads After Surgery
This research examines tissue samples from patients who had surgery to remove advanced esophageal cancer in the neck or chest area. The study aims to understand how the cancer invaded surrounding tissues, which may help doctors better treat similar patients in the future.
ShanghaiAges Any age - NCT06349980RecruitingPhase 2
Study of three drugs for liver cancer not yet treated
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
ShanghaiAges 18 years+ - NCT07545356RecruitingPhase 1
Testing KIVU-305 for Advanced Solid Tumors
This study tests a new cancer drug called KIVU-305 in people with advanced or metastatic solid tumors (cancer that has spread) that haven't responded to standard treatments. The drug is designed to target cancer cells while minimizing harm to healthy cells.
Sydney, New South WalesAges 18 years+ - NCT07550972Enrolling by invitationPhase 2
Combination drug treatment before surgery for advanced head and neck cancer
This study tests two drugs (pertuzumab and lenvatinib) given together before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve outcomes for patients who haven't received prior cancer treatment.
Hangzhou, ZhejiangAges 18–75 - NCT07535112RecruitingPhase 1
Study of a new drug for advanced colorectal cancer with KRAS G12D mutation
This trial tests an experimental drug (BAY 3771249) for people with advanced or metastatic colorectal cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and if it can help shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT06749886RecruitingPhase 2
Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
ShanghaiAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06016062RecruitingPhase 1/Phase 2
Study of RC148 for advanced solid tumors
This trial tests a new drug called RC148, both alone and combined with other treatments, for people with advanced solid tumors that haven't responded to standard therapy. It includes several groups for specific cancers (like non-small cell lung, cervical, stomach, and ovarian cancer) to see if RC148 can shrink tumors or slow their growth.
AnhuiAges 18 years+ - NCT07448077RecruitingPhase 2
Short radiation with immunotherapy for rectal cancer
This trial tests a combination of short-course radiation, chemotherapy, and an immunotherapy drug (Enlonstobart) for patients with a specific type of rectal cancer called pMMR. It aims to see if this approach can shrink tumors before surgery and improve outcomes.
Shijiazhuang, HebeiAges 18 years+ - NCT07403721RecruitingPhase 1
Study of AMG 436 for MSI-H/dMMR Cancers
This study tests an experimental drug called AMG 436, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change (MSI-H or dMMR). The goal is to see if the drug can shrink tumors and if it is safe.
Irvine, CaliforniaAges 18–99 - NCT07405151RecruitingPhase 1/Phase 2
New drug for advanced esophageal cancer after other treatments
This trial tests a new drug called Ifinatamab Deruxtecan for people with advanced esophageal squamous cell carcinoma that has progressed after one or two prior treatments. It aims to see if the drug can shrink tumors or slow the disease.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07404332RecruitingPhase 1
Combination therapy for tumors resistant to immunotherapy
This trial tests a combination of two drugs (5-Azacitidine and a PD-1/PD-L1 inhibitor) for people whose solid tumors stopped responding to standard PD-1/PD-L1 immunotherapy alone. The goal is to see if this new combination can help shrink the tumor or slow its growth.
Iowa City, IowaAges 18–99 - NCT07394374RecruitingPhase 1/Phase 2
CG001419 Tablets for Advanced Solid Tumors with NTRK Changes
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
BeijingAges 18 years+ - NCT06762405RecruitingPhase 3
Testing dostarlimab with short radiation for MSI rectal cancer
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
DijonAges 18 years+ - NCT07365592RecruitingPhase 1/Phase 2
Neoadjuvant therapy for locally advanced colorectal cancer
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07364357RecruitingPhase 1
Study of CREPT-618 for advanced liver cancer
This phase 1 trial tests a new drug called CREPT-618 for people with advanced liver cancer that hasn't responded to standard treatments. The drug is designed to target cancer cells with specific markers (CREPT and ASGPR), so only patients whose tumors have these markers can join.
BeijingAges 18–75 - NCT07362186RecruitingPhase 3
LM-108 with Toripalimab vs Paclitaxel for advanced stomach cancer
This trial tests a new combination of two immunotherapy drugs (LM-108 and Toripalimab) against a standard chemotherapy drug (Paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CCR8. It may be an option if you have already tried a first-line therapy and your cancer has progressed or you had side effects from chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07367529RecruitingPhase 1/Phase 2
TQB6411 for injection for lung cancer
This trial tests a new drug called TQB6411 for people with lung cancer that can be measured by scans. The drug is given by injection, and the study will see if it is safe and if it helps shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07346248Enrolling by invitation
Complications after pre-surgery treatment for advanced rectal cancer
This study looks at complications that happen after surgery in patients with advanced rectal cancer who got radiation or chemo-radiation before their operation. Researchers want to learn how different pre-surgery treatments affect recovery.
Rozzano, MilanAges 18 years+
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,515 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.